Y
Yizun Biopharmaceutical
Yizun Biotech offers cell therapy solutions, including universal technologies for treating solid tumors and allogeneic cells
About Yizun Biopharmaceutical
Yizun Biopharmaceutical (Zhejiang) Co., Ltd. is a clinical-stage biopharmaceutical entity established in 2018, concentrating on the development of cell therapies for solid tumors. The company was co-founded by Dr. Liu Lingfeng, an expert in immunotherapy, and Mr. Guo Xiaobin, who contributes extensive experience in investment and innovation incubation. Dr. Liu's background includes direct participation in CAR-T cell therapy development and clinical research at the Fred Hutchinson Cancer Research Center in the U.S., where he secured several international patents, some of which were licensed to Juno Therapeutics.
The company's core business revolves around the research and development of treatments for solid tumors and allogeneic cells, with a specific focus on accelerating the creation of allogeneic cell drugs for advanced liver cancer. Yizun Biopharmaceutical operates on a model that involves developing proprietary technology platforms and advancing product pipelines through clinical trials. It has established three primary technology platforms: CNK-T, VAC-T, and UT. The CNK-UT platform, in particular, demonstrated initial clinical efficacy in treating liver cancer in July 2020.
Revenue generation is intrinsically tied to the successful development and subsequent commercialization or licensing of its therapeutic products. The company has secured significant funding to support its operations, including a Pre-A round in June 2019 from Livzon Pharm, a Series A round in January 2022 co-led by VMS and Shenzhen Capital, and a Series A1 round in April 2024. These funds are allocated towards talent acquisition, R&D, clinical trials, and optimizing its technology platforms. To facilitate its research and production, the company operates a nearly 3,000-square-meter GMP production workshop and clinical transformation center in Hangzhou.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $14M | $55M | Tailong Investment · Tigeryeah Capital · Hangzhou Binjiang 5050 Fund | ↗ |
| SERIES A✓Equity / VC | May 2022 | $14M | $55M | Dingpei Group · Shenzhen Capital Group | — |
Growth signals
Latest recorded traffic for Yizun Biopharmaceutical is 230 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yizun Biopharmaceutical in the Hangzhou ecosystem
The Yizun Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Livzon Pharmaceutical Group
VMS Capital
Shenzhen Capital Group
Tao Capital Partners- TCTEDA Venture Capital
Panacea Venture- DGDingpei Group
- TITailong Investment
- TCTigeryeah Capital
- HFHangzhou Binjiang 5050 Fund
Other known investors2 additional known investors
Fred Hutchinson Cancer Research Center
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yizun Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yizun Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









